Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment ConferenceGlobeNewsWire • 10/11/23
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and SoftwareGlobeNewsWire • 09/19/23
Certara & Xybion Partner to Integrate Nonclinical R&D Software to Streamline Assessing Drug Safety & EfficacyAccesswire • 08/08/23
Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND datasetBusiness Wire • 08/04/23
Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 05/01/23
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive YearGlobeNewsWire • 04/27/23
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare ConferenceGlobeNewsWire • 04/10/23
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?Zacks Investment Research • 03/09/23
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic typesGlobeNewsWire • 03/07/23